The Aryavarth Express
Munchen: It is now simpler to differentiate between primary tauopathy and Alzheimer’s thanks to a novel biomarker.
Patients with illnesses so uncommon and specialised that private practice doctors seldom ever hear of them frequently present themselves to academic hospitals. One example is primary 4-repeat tauopathies. These are conditions mainly linked to movement abnormalities, although it can be challenging to get a definitive diagnosis because the symptoms frequently match those of Alzheimer’s disease. Physicians can now accurately differentiate between the two illnesses thanks to biomarkers discovered by researchers at LMU University Hospital, but they can only do so using information from positron emission tomography (PET) scans.
“The new diagnostic algorithm we developed allows physicians to differentiate with greater precision between Alzheimer’s disease and primary tauopathies, which facilitates earlier and more precise diagnosis and supports personalised treatment strategies,” says principal investigator Professor Matthias Brendel, acting director of the Department of Nuclear Medicine and member of the SyNergy Cluster of Excellence. The results have now been published in the journal of the Alzheimer’s Association, Alzheimer’s and dementia.
In Alzheimer’s disease and primary 4-repeat tauopathies, large pathological aggregates of the tau protein are found in the brain. For decades. It has been possible to detect tau proteins for Alzheimer’s disease by analysing the patient’s cerebrospinal fluid (CSF).
In recent times, however, researchers have developed radioactively labelled substances (tracers) that accumulate at the tau aggregates after injection into the body, which are visible on the PET images. “Our new study shows that tau can be identified with the novel tau PET tracer even in 4-reapet tauopathies—but not in the cerebrospinal fluid, rather in very specific areas of the brain known as the subcortical brain regions,” explained Roxane Dilcher, lead author of the study.
However, the PET signal is just one component of a complex new diagnostic process. The researchers have additionally found new biomarkers that indicate the presence of a 4-repeat tauopathy. “Diagnostic gets really effective when we analyse a combination of cerebrospinal fluid tests, innovative biomarkers, and PET signals in the subcritical regions,” says Matthias Brendel. “Then we can recognise a 4-repeat tauopathy with a high degree of certainty.”
“Primary 4-repeate tauopathies are diagnosed almost exclusively using clinical at present—without specific biomarkers that enable conclusive diagnosis in patients,” says co-senior author Dr. Nicolai Franzmeier, who is also a member of SyNergy. “The establishment of a biological definition and corresponding biomarker workflows will decidedly advance the research field.
